RecruitingNCT06627335

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Pregnancy Outcomes Study of Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Sponsor

Incyte Corporation

Enrollment

5,621 participants

Start Date

Mar 27, 2023

Study Type

OBSERVATIONAL

Conditions

Atopic Dermatitis Pregnancy Related

Summary

This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.

Eligibility

Sex: FEMALEMin Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ruxolitinib Cream and a drug called TCS for people with atopic dermatitis and pregnancy related. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 14 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.